Melanie Sena

GSK reported that the Court of Appeals has ruled against Pronova Biopharma Norge AS in its patent litigation regarding Lovaza.

AstraZeneca and Merck & Co. form a licensing agreement for Merck?s oral small-molecule drug for ovarian cancer.

For the 2013-2014 academic year, three $50,000 USP Global Fellowship awards have been presented.

Takeda's drug vedolizumab is granted priority review status for the treatment of adults with moderately to severely active ulcerative colitis.

MPI's new Imaging Center is set to open in Spring 2014 at the company's headquarters in Michigan.

FDA approves BD Simplist product ondansetron injection, an injectable antiemetic.

The California State Assembly becomes the latest state to specify requirements allowing substitution of biosimilars.

Johnson & Johnson completes acquisition deal with Aragon Pharmaceuticals.

ATCC creates Biomaterial Contributor Network to assist the research community.

James Stewart named CIO of Merck KGaA.

The Russian pharmaceutical company PharmaStand finalizes deal for acquiring Bever, a Singapore pharma company.

Eisai files a petition with federal appeals court to require the Drug Enforcement Agency to put anti-epilepsy drug Fycompa on the controlled list of substances.

Sangamo BioSciences has agreed to acquire Ceregene, a privately held biotechnology company focused on developing adeno-associated virus (AAV) gene therapies.

Akorn will acquire Hi-Tech Pharmacal for $640 million.

AstraZeneca's MedImmune has agreed to acquire Amplimmune, which specializes in cancer immunology.

Santaris Pharma and Shire have extended their partnership in the rare genetic disease space.

Amgen acquires Onyx Pharmaceuticals for $125 per share in cash.

Parameter Stability Storage adds validated space in anticipation of pending contracts.

The fund's first investment will be in SetPoint Medical, a California company.

ViiV Healthcare, a specialist HIV pharmaceutical company of GSK, Pfizer, and Shionogi gains approval for new HIV-1 treatment.

Alpha Packaging's new line will consist of more than a dozen injection blow molded and extrusion blow molded bottles.

The new business development office is located in Massachusetts.

The companies initially focused on five biosimilar products.

A new study reveals how a promising anticancer specifically kills prostate cancer cells by compromising their ability to withstand environmental stress.

Weill Cornell scientists reveal how a protein drug eradicated human lymphoma in mice.

Funding awarded to develop innovative solutions that address unmet health needs.

Additional investment from the Biomedical Catalyst will fund multiple programs in the UK.

Bristol-Myers Squibb Company and Samsung BioLogics announced the companies have entered into a 10-year agreement.

Pfizer has announced plans to internally separate its commercial operations into three business segments.

Kemwell Biopharma announced that it has acquired Cirrus Pharmaceuticals Inc., a contract development services company based in Research Triangle Park, N.C.